HCWB — Hcw Biologics Income Statement
0.000.00%
Last trade - 00:00
- $63.54m
- $66.25m
- $2.84m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 4.1 | 0 | 6.72 | 2.84 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 2.59 | 0.56 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.37 | 9.92 | 12.8 | 21.8 | 28.6 |
Operating Profit | -7.37 | -5.82 | -12.8 | -15.1 | -25.7 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.29 | -5.8 | -12.9 | -14.9 | -25 |
Net Income After Taxes | -7.29 | -5.8 | -12.9 | -14.9 | -25 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.29 | -5.8 | -12.9 | -14.9 | -25 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.78 | -7.07 | -12.9 | -14.9 | -25 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.218 | -0.198 | -0.375 | -0.416 | -0.696 |